Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 3, 2008, Pages 959-962

  Ducray, Richard ^a   Ballard, Peter ^a   Barlaam, Bernard C ^a   Hickinson, Mark D ^a   Kettle, Jason G ^a   Ogilvie, Donald J ^a   Trigwell, Catherine B ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

erbB2; Pyrazolopyrimidines; Receptor tyrosine kinase

Indexed keywords

3 ALKOXY 4 ANILINO 1H PYRAZOL[3,4 D]PYRIMIDINE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DRUG BIOAVAILABILITY; DRUG INHIBITION; DRUG SYNTHESIS; FEMALE; IN VITRO STUDY; MALE; NONHUMAN; RAT;

ANIMALS; COMBINATORIAL CHEMISTRY TECHNIQUES; DOGS; DRUG DESIGN; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIMIDINES; RATS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, ERBB-2;

CANIS FAMILIARIS; RATTUS;

EID: 38849184695     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.12.035     Document Type: Article

References (20)

1. Reid A., Vidal L., Shaw H., and de Bono J. Eur. J. Cancer 43 (2007) 481
2. Hynes N.E., and Lane H.A. Nat. Rev. Cancer 5 (2005) 341
3. Engel R.H., and Kaklamani V.G. Drugs 67 (2007) 1329
4. Moy B., Kirkpatrick P., Kar S., and Goss P. Nat. Rev. Drug Discov. 6 (2007) 431
5. Traxler P., Allegrini P.R., Brandt R., Brueggen J., Cozens R., Fabbro D., Grosios K., Lane H.A., McSheehy P., Mestan J., Meyer T., Tang C., Wartmann M., Wood J., and Caravatti G. Cancer Res. 64 (2004) 4931
6. Wong T.W., Lee F.Y., Yu C., Luo F.R., Oppenheimer S., Zhang H., Smykia R.A., Mastalerz H., Fink B.E., Hunt J.T., Gavai A.V., and Vite G.D. Clin. Cancer Res. 12 (2006) 6186
7. Rabindran S.K., Discfani C.M., Rosfjord E.C., Baxter M., Floyd M.B., Golas J., Hallett W.A., Johnson B.D., Nilakantan R., Overbeek E., Reich M.F., Shen R., Shi X., Tsou H.-R., Wang Y.-F., and Wissner A. Cancer Res. 64 (2004) 3958
8. Solca, F.; Baum, A.; Himmelsbach, F.; Amelsberg, A.; Adolf, G. Eur J Cancer - Suppl. 2006, 4(12) Abst 567. See also Ref. 1a.
9. Jani J.P., Finn R.S., Campbell M., Coleman K.G., Connell R.D., Currier N., Emerson E.O., Floyd E., Harriman S., Kath J.C., Morris J., Moyer J.D., Pustilnik L.R., Rafidi K., Ralston S., Rossi A.M.K., Steyn S.J., Wagner L., Winter S.M., and Bhattacharya S.K. Cancer Res. 67 (2007) 9887
10. For a related series of selective erbB2 inhibitors, see also. Lippa B., Kauffman G.S., Arcari J., Kwan T., Chen J., Hungerford W., Bhattacharya S., Zhao X., Williams C., Xiao J., Pustilnik L., Su C., Moyer J.D., Ma L., Campbell M., and Steyn S. Bioorg. Med. Chem. Lett. 17 (2007) 3081
11. Ballard P., Bradbury R.H., Hennequin L.F.A., Hickinson D.M., Johnson P.D., Kettle J.G., Klinowska T., Morgentin R., Ogilvie D.J., and Olivier A. Bioorg. Med. Chem. Lett. 15 (2005) 4226
12. Traxler P., Bold G., Frei J., Lang M., Lydon N., Mett H., Buchdunger E., Meyer T., Mueller M., and Furet P. J. Med. Chem. 40 (1997) 3601
13. see also. Wu T.Y.H., Schultz P.G., and Ding S. Org. Lett. 5 (2003) 3587
14. Middleton W.J., and Engelhardt V.A. J. Am. Chem. Soc. 80 (1958) 2822
15. Neidlein R., and Kikelj D. Synthesis (1988) 981
16. For a similar transformation, see:. Ugarkar B.G., Castellino A.J., DaRe J.M., Kopcho J.J., Wiesner J.B., Schanzer J.M., and Erion M.D. J. Med. Chem. 43 (2000) 2894
17. For experimental procedures and description of kinase and clone 24 assays, see: Barlaam, B.C., Ducray, R., Kettle, J.G. PCT Int. Appl. WO2006064196.
18. Middleton W.J., and Engelhardt V.A. J. Am. Chem. Soc. 80 (1958) 2788
19. Replacement of the 2-pyridyl group in compound 12k by a 3-fluorophenyl led to a significant decrease of the unbound fraction in rat plasma (from 10% to 0.9% free drug).
20. 50 values of 5 in erbB2 and EGFR kinase inhibition assays are, respectively, 0.002 and 0.14 μM (see Ref. 8).